Monkeypox immunisation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Monkeypox immunisation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Different Doses of MVA-BN Vaccine Booster for Adults with Mpox: Comparing Standard and Reduced Doses https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-lower-dose-booster-vaccine-for-mpox-using-modified-vaccinia-ankara-in-adults/ Wed, 29 Apr 2026 15:05:27 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-lower-dose-booster-vaccine-for-mpox-using-modified-vaccinia-ankara-in-adults/ This study focuses on mpox (formerly known as monkeypox) and investigates the effectiveness of booster vaccinations using IMVANEX, which contains Modified Vaccinia Ankara virus. The vaccine is given as an injection under the skin (subcutaneous injection), and the study compares two different doses of the same vaccine – a standard dose and a reduced dose.

The purpose of this research is to determine if a smaller dose of the vaccine can provide the same level of protection against mpox virus as the standard dose when given as a booster shot. The vaccine contains a modified form of the vaccinia virus that has been altered to be safe while still helping the body develop protection against mpox.

During the study, participants will receive one booster dose of the vaccine and will be monitored for six months. The study will measure the body’s immune response by checking for protective substances (antibodies) in the blood. Healthcare providers will also track any reactions or side effects that may occur after vaccination. Blood samples will be collected at specific times to measure how well the vaccine is working.

]]> Study on the Effectiveness of Modified Vaccinia Ankara Vaccine in Preventing Mpox Infection in Adults https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-modified-vaccinia-ankara-vaccine-in-preventing-mpox-infection-in-adults/ Wed, 29 Apr 2026 14:47:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-modified-vaccinia-ankara-vaccine-in-preventing-mpox-infection-in-adults/ This clinical trial is focused on studying the prevention of Mpox infection, which is a disease caused by a virus similar to the one that causes smallpox. The study will use a vaccine called IMVANEX, which is a suspension for injection containing a live virus known as Modified Vaccinia Ankara – Bavarian Nordic Live Virus. This vaccine is designed to help the body build protection against the Mpox virus.

The purpose of the study is to understand how the body’s immune response, specifically the antibodies that fight the virus, changes over time after receiving the vaccine. Participants in the study will receive either one or two doses of the vaccine. The study will monitor the levels of these antibodies at different times, up to 48 weeks after vaccination. This will help researchers learn more about how long the vaccine’s protection lasts and what factors might influence this.

Throughout the study, participants will have regular check-ups to measure the presence of antibodies and to ensure their well-being. The study will also look at the vaccine’s ability to neutralize the virus in laboratory settings and check for any other infections that might occur during the study period. This research aims to provide valuable information on the effectiveness of the IMVANEX vaccine in preventing Mpox infection.

]]>